Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 76


A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology Derived Injectable Drug Products.

Mathonet S, Mahler HC, Esswein ST, Mazaheri M, Cash PW, Wuchner K, Kallmeyer G, Das T, Finkler C, Lennard A.

PDA J Pharm Sci Technol. 2016 Apr 18. pii: pdajpst.2015.006189. [Epub ahead of print]


A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma.

de Baaij LR, Berkhof J, van de Water JM, Sieniawski MK, Radersma M, Verbeek WH, Visser OJ, Oudejans JJ, Meijer CJ, Mulder CJ, Lennard AL, Cillessen SA.

Clin Cancer Res. 2015 Jul 1;21(13):3013-9. doi: 10.1158/1078-0432.CCR-14-2195. Epub 2015 Mar 16.


Anaplastic large cell lymphoma in a reconstructed breast using a silicone implant: a UK case report.

Sørensen K, Murphy J, Lennard A, Wadehra V, Menon GK, Collis N.

J Plast Reconstr Aesthet Surg. 2014 Apr;67(4):561-3. doi: 10.1016/j.bjps.2013.09.015. Epub 2013 Sep 18.


Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study.

Wirth A, Gospodarowicz M, Aleman BM, Bressel M, Ng A, Chao M, Hoppe RT, Thieblemont C, Tsang R, Moser L, Specht L, Szpytma T, Lennard A, Seymour JF, Zucca E.

Ann Oncol. 2013 May;24(5):1344-51. doi: 10.1093/annonc/mds623. Epub 2013 Jan 4.


Enteropathy-associated T-cell lymphoma: epidemiology, clinical features, and current treatment strategies.

Sieniawski MK, Lennard AL.

Curr Hematol Malig Rep. 2011 Dec;6(4):231-40. doi: 10.1007/s11899-011-0097-7. Review.


Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia.

Jovanovic JV, Rennie K, Culligan D, Peniket A, Lennard A, Harrison J, Vyas P, Grimwade D.

Front Oncol. 2011 Oct 25;1:35. doi: 10.3389/fonc.2011.00035. eCollection 2011.


Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.

Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, Jack F, Lyons S, Mounter P, Revell P, Proctor SJ, Lennard AL.

Blood. 2010 May 6;115(18):3664-70. doi: 10.1182/blood-2009-07-231324. Epub 2010 Mar 2. Erratum in: Blood. 2011 Feb 10;117(6):2077.


The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control.

Proctor SJ, Lennard AL, Jackson GH, Jones GL, Lewis J, Wilkinson J, White J, Sieniawski M, McKay P, Culligan D, Lucraft HH.

Ann Oncol. 2010 Feb;21(2):426-8. doi: 10.1093/annonc/mdp527. Epub 2009 Nov 9. Review. No abstract available.


Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.

Hasan SK, Mays AN, Ottone T, Ledda A, La Nasa G, Cattaneo C, Borlenghi E, Melillo L, Montefusco E, Cervera J, Stephen C, Satchi G, Lennard A, Libura M, Byl JA, Osheroff N, Amadori S, Felix CA, Voso MT, Sperr WR, Esteve J, Sanz MA, Grimwade D, Lo-Coco F.

Blood. 2008 Oct 15;112(8):3383-90. doi: 10.1182/blood-2007-10-115600. Epub 2008 Jul 23.


Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.

Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, Roos D, Lennard A, Devizzi L, Crabb S, Hossfeld D, Pratt G, Dell'Olio M, Choo SP, Bociek RG, Radford J, Lade S, Gianni AM, Zucca E, Cavalli F, Seymour JF; International Extranodal Lymphoma Study Group.

Ann Oncol. 2008 Feb;19(2):233-41. Epub 2007 Oct 11.


Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.

Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP, Lennard AL, Pallan L, Arrazi JM, Perz JB, O'Shea D, Goldman JM, Apperley JF, Craddock CF.

Blood. 2007 Dec 15;110(13):4614-7. Epub 2007 Sep 19.


Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T-cell lymphoma.

Lennard A.

Br J Haematol. 2007 Apr;137(2):170; author reply 171. No abstract available.


Cellular Notch responsiveness is defined by phosphoinositide 3-kinase-dependent signals.

McKenzie G, Ward G, Stallwood Y, Briend E, Papadia S, Lennard A, Turner M, Champion B, Hardingham GE.

BMC Cell Biol. 2006 Feb 28;7:10.


Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.

Irving JA, O'Brien S, Lennard AL, Minto L, Lin F, Hall AG.

Clin Chem. 2004 Jul;50(7):1233-7. No abstract available.


Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia.

Drummond M, Lennard A, Brûmmendorf T, Holyoake T.

Leuk Lymphoma. 2004 Sep;45(9):1775-81.


Akt mediates insulin-stimulated phosphorylation of Ndrg2: evidence for cross-talk with protein kinase C theta.

Burchfield JG, Lennard AJ, Narasimhan S, Hughes WE, Wasinger VC, Corthals GL, Okuda T, Kondoh H, Biden TJ, Schmitz-Peiffer C.

J Biol Chem. 2004 Apr 30;279(18):18623-32. Epub 2004 Feb 24.


Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.

Drummond MW, Marin D, Clark RE, Byrne JL, Holyoake TL, Lennard A; United Kingdom Chronic Myeloid Leukaemia (UK CML) Working Party.

Br J Haematol. 2003 Nov;123(3):479-83.


Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.

Marin D, Marktel S, Bua M, Szydlo RM, Franceschino A, Nathan I, Foot N, Crawley C, Na Nakorn T, Olavarria E, Lennard A, Neylon A, O'Brien SG, Goldman JM, Apperley JF.

Leukemia. 2003 Aug;17(8):1448-53.


Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK).

Proctor SJ, Jackson GH, Lennard A, Angus B, Wood K, Lucraft HL, White J, Windebank K, Taylor PR; Northern Region Lymphoma Group.

Ann Oncol. 2003;14 Suppl 1:i47-50.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk